Soichi KOJIMA Kiminori USHIDA Yoshiko OKAMOTO Jeff
... Uptake through glycoprotein 2 (GP2) of FimH+ bacteria by M cells initiates mucosal immune response ...
... Uptake through glycoprotein 2 (GP2) of FimH+ bacteria by M cells initiates mucosal immune response ...
T cell coinhibition in prostate cancer: new immune evasion pathways and
... vaccines are designed to bolster tumor antigen presentation, most do not address the immune evasion pathways that suppress T cell function. T cell coinhibition as immune evasion mechanisms in prostate cancer Prostate cancer can escape immune responses via a variety of mechanisms [20]. A prime exampl ...
... vaccines are designed to bolster tumor antigen presentation, most do not address the immune evasion pathways that suppress T cell function. T cell coinhibition as immune evasion mechanisms in prostate cancer Prostate cancer can escape immune responses via a variety of mechanisms [20]. A prime exampl ...
Common Variable Immunodeficiency
... Inhibit wide range of immune responses – To self – To pathogens Transcription ...
... Inhibit wide range of immune responses – To self – To pathogens Transcription ...
About and Key Statistics - American Cancer Society
... Some newer drugs, such as nivolumab (Opdivo) and pembrolizumab (Keytruda), work by blocking these checkpoints, which can boost the immune response against cancer cells in the body. These drugs have shown promising results against Hodgkin lymphoma, even in people who have already had several other t ...
... Some newer drugs, such as nivolumab (Opdivo) and pembrolizumab (Keytruda), work by blocking these checkpoints, which can boost the immune response against cancer cells in the body. These drugs have shown promising results against Hodgkin lymphoma, even in people who have already had several other t ...
Eds., Y. Obayashi, T. Isobe, A. Subramanian, S. Suzuki and... © by TERRAPUB, 2009.
... In human hybridoma cells, methoxychlor, α- and β-endosulfan slightly decreased the amount of IgM in culture medium and cell viability at low dose. The intensive toxic effects of these pesticides were not observed between 0.01 to 1 µM. However, the toxicity increased dose-dependently at higher concen ...
... In human hybridoma cells, methoxychlor, α- and β-endosulfan slightly decreased the amount of IgM in culture medium and cell viability at low dose. The intensive toxic effects of these pesticides were not observed between 0.01 to 1 µM. However, the toxicity increased dose-dependently at higher concen ...
the_large_1 - Salk Institute
... One example of such an infectious agent is the vertically transmitted mouse mammary tumor virus which uses this time-window in mice to be treated as an NTBR-antigen. ...
... One example of such an infectious agent is the vertically transmitted mouse mammary tumor virus which uses this time-window in mice to be treated as an NTBR-antigen. ...
The effect of differential phosphorylation of YB-1 on apoptosis
... The YB-1 protein is involved in several cellular processes, such as proliferation, differentiation and response to stress. In order to examine its physiological role in vivo, Lu et. al produced homozygous mice with a true null mutation in the YB-1 gene. They discovered that YB-1 is vital for the dev ...
... The YB-1 protein is involved in several cellular processes, such as proliferation, differentiation and response to stress. In order to examine its physiological role in vivo, Lu et. al produced homozygous mice with a true null mutation in the YB-1 gene. They discovered that YB-1 is vital for the dev ...
A Symposium on Cell Signaling - NMC Conferences Home
... Keynote Speaker: Byron Goldstein, LANL (Honoree) Dr. Byron Goldstein is a retired Fellow of the Los Alamos National Laboratory. He is a recipient of the 2003 National Institute of General Medical Sciences ...
... Keynote Speaker: Byron Goldstein, LANL (Honoree) Dr. Byron Goldstein is a retired Fellow of the Los Alamos National Laboratory. He is a recipient of the 2003 National Institute of General Medical Sciences ...
The Living World - Chapter 27 - McGraw Hill Higher Education
... observed that milkmaids who got cowpox rarely got smallpox He inoculated patients with cowpox and thus protected them from smallpox Fig. 22.19 Copyright ©The McGraw-Hill Companies, Inc. Permission required for reproduction or display ...
... observed that milkmaids who got cowpox rarely got smallpox He inoculated patients with cowpox and thus protected them from smallpox Fig. 22.19 Copyright ©The McGraw-Hill Companies, Inc. Permission required for reproduction or display ...
The Living World
... observed that milkmaids who got cowpox rarely got smallpox He inoculated patients with cowpox and thus protected them from smallpox Fig. 27.19 Copyright ©The McGraw-Hill Companies, Inc. Permission required for reproduction or display ...
... observed that milkmaids who got cowpox rarely got smallpox He inoculated patients with cowpox and thus protected them from smallpox Fig. 27.19 Copyright ©The McGraw-Hill Companies, Inc. Permission required for reproduction or display ...
Basic Concepts of Immune Response and Defense Development
... Théry and Amigorena 2001). This process is critically important in defending against intracellular pathogens such as viruses and certain bacteria. The Tc lymphocyte responses are also essential in the immune defense against tumors due to their role in recognizing antigens presented in the context of ...
... Théry and Amigorena 2001). This process is critically important in defending against intracellular pathogens such as viruses and certain bacteria. The Tc lymphocyte responses are also essential in the immune defense against tumors due to their role in recognizing antigens presented in the context of ...
Parasite Immunology 2015 pre print - T-Stor
... 116 surfaces and tissue immune cells such macrophages and dendritic cells, the major antigen 117 presenting cells (APCs) (32, 33). PRR proteins identify both pathogen-associated molecular 118 patterns (PAMPs; pathogen molecular structures not found in the host), and damage 119 associated molecular p ...
... 116 surfaces and tissue immune cells such macrophages and dendritic cells, the major antigen 117 presenting cells (APCs) (32, 33). PRR proteins identify both pathogen-associated molecular 118 patterns (PAMPs; pathogen molecular structures not found in the host), and damage 119 associated molecular p ...
OX40 ligand expression abrogates the immunosuppressive function
... of retinal pigment epithelium (RPE)-mediated immunosuppression using an in vitro expression approach. OX40L cDNA was polymerase chain reaction-amplified and cloned into an eYFP fusion vector. Cultured retinal pigment epithelial cells (ARPE-19) were transfected with the vector. Total RNA from unstimu ...
... of retinal pigment epithelium (RPE)-mediated immunosuppression using an in vitro expression approach. OX40L cDNA was polymerase chain reaction-amplified and cloned into an eYFP fusion vector. Cultured retinal pigment epithelial cells (ARPE-19) were transfected with the vector. Total RNA from unstimu ...
Basic Concepts of Immune Response and Defense Development
... oxynucleotide (CpG-ODN1)-motifs, which stimulate cells such as DCs through Toll-like receptors (TLRs1) (Diefenbach and Raulet 2003; Gordon 2002; Netea et al. 2004). The critical interaction between the innate and specific parts of the immune system involves the role played by antigen-presenting cel ...
... oxynucleotide (CpG-ODN1)-motifs, which stimulate cells such as DCs through Toll-like receptors (TLRs1) (Diefenbach and Raulet 2003; Gordon 2002; Netea et al. 2004). The critical interaction between the innate and specific parts of the immune system involves the role played by antigen-presenting cel ...
poster template - Argos Therapeutics
... Statistically significant increases in CD28 expressing CTL can be detected during booster treatment with AGS-003 CTL within the CD28+ central/memory subset maintain broad multi-functionality AGS-003 immunotherapy in combination with sunitinib results in long term decreases in both MDSC and T r ...
... Statistically significant increases in CD28 expressing CTL can be detected during booster treatment with AGS-003 CTL within the CD28+ central/memory subset maintain broad multi-functionality AGS-003 immunotherapy in combination with sunitinib results in long term decreases in both MDSC and T r ...
of Tumor Origin Influence in Colorectal and Renal Cell Carcinoma
... 0.0001) were observed in colorectal carcinoma as compared to RCC metastases, whereas densities of T cells were similar. High densities of CD8þ and DC-LAMPþ cells correlated with longer overall survival (OS) in colorectal carcinoma (P ¼ 0.008) and shorter OS in RCC (P < 0.0001). High NK-cell densitie ...
... 0.0001) were observed in colorectal carcinoma as compared to RCC metastases, whereas densities of T cells were similar. High densities of CD8þ and DC-LAMPþ cells correlated with longer overall survival (OS) in colorectal carcinoma (P ¼ 0.008) and shorter OS in RCC (P < 0.0001). High NK-cell densitie ...
Immune - anslab.iastate.edu
... (CD4- & CD8-). The TCR function is unknown. These CD4-/CD8- are able to kill non-specifically, are not restricted by either MHC class I or II molecules, and are capable of both antibody dependant cell mediated cytotoxicity (ADCC) or cell destruction in the absence of antibody. There is a high freque ...
... (CD4- & CD8-). The TCR function is unknown. These CD4-/CD8- are able to kill non-specifically, are not restricted by either MHC class I or II molecules, and are capable of both antibody dependant cell mediated cytotoxicity (ADCC) or cell destruction in the absence of antibody. There is a high freque ...
Addressing the Inflammatory Response to Clinically Relevant
... immunosurveillance mechanisms that drive the host reaction to biomaterials. Specifically, these materials are largely designed to prevent the initial steps of the inflammatory process by preventing cell-material interactions [33]. Generally, the coatings used to make a bioinert surface tend to be hy ...
... immunosurveillance mechanisms that drive the host reaction to biomaterials. Specifically, these materials are largely designed to prevent the initial steps of the inflammatory process by preventing cell-material interactions [33]. Generally, the coatings used to make a bioinert surface tend to be hy ...
gp allergy 310713
... Type II – immune complex – antigen membrane bound Type III – immune complex – antigen “circulating” Type IV – cell (T) mediated ...
... Type II – immune complex – antigen membrane bound Type III – immune complex – antigen “circulating” Type IV – cell (T) mediated ...
CYTOKINES AS TARGETS FOR IMMUNOMODULATION Review Article SHADMA WAHAB
... are a promising target for new drugs to help regulate immune responses. Clinical studies are underway to test its benefits in diseases such as cancer, hepatitis C, and HIV infection and AIDS. Scientists are studying other cytokines to see whether they can also be used to treat diseases. [3, 4] Funct ...
... are a promising target for new drugs to help regulate immune responses. Clinical studies are underway to test its benefits in diseases such as cancer, hepatitis C, and HIV infection and AIDS. Scientists are studying other cytokines to see whether they can also be used to treat diseases. [3, 4] Funct ...
Chapter 22 Lympahatic System
... Processing of Endogenous Antigens • Endogenous antigens are foreign proteins produced within a body cell --- viral or cancerous • Fragments of weird proteins become part of MHC-I molecules displayed at surface of cell • Signals that a cell need help because it is infected or has turned cancerous ...
... Processing of Endogenous Antigens • Endogenous antigens are foreign proteins produced within a body cell --- viral or cancerous • Fragments of weird proteins become part of MHC-I molecules displayed at surface of cell • Signals that a cell need help because it is infected or has turned cancerous ...
Immune System - Iowa State University Digital Repository
... cells in the nervous system, Langerhans cells in the skin, and Kupffer cells in the liver. Macrophages are capable of all the activities described above for neutrophils. Macrophages are said to be the second line of defense but are slower to arrive at sites of inflammation and are not as aggressive ...
... cells in the nervous system, Langerhans cells in the skin, and Kupffer cells in the liver. Macrophages are capable of all the activities described above for neutrophils. Macrophages are said to be the second line of defense but are slower to arrive at sites of inflammation and are not as aggressive ...
Cancer immunotherapy
Cancer immunotherapy (immuno-oncology) is the use of the immune system to treat cancer. Immunotherapies fall into three main groups: cellular, antibody and cytokine. They exploit the fact that cancer cells often have subtly different molecules on their surface that can be detected by the immune system. These molecules, known as cancer antigens, are most commonly proteins, but also include molecules such as carbohydrates. Immunotherapy is used to provoke the immune system into attacking the tumor cells by using these antigens as targets.Antibody therapies are the most successful immunotherapy, treating a wide range of cancers. Antibodies are proteins produced by the immune system that bind to a target antigen on the cell surface. In normal physiology the immune system uses them to fight pathogens. Each antibody is specific to one or a few proteins. Those that bind to cancer antigens are used to treat cancer. Cell surface receptors are common targets for antibody therapies and include the CD20, CD274, and CD279. Once bound to a cancer antigen, antibodies can induce antibody-dependent cell-mediated cytotoxicity, activate the complement system, or prevent a receptor from interacting with its ligand, all of which can lead to cell death. Multiple antibodies are approved to treat cancer, including Alemtuzumab, Ipilimumab, Nivolumab, Ofatumumab, and Rituximab.Cellular therapies, also known as cancer vaccines, usually involve the removal of immune cells from the blood or from a tumor. Immune cells specific for the tumor are activated, cultured and returned to the patient where the immune cells attack the cancer. Cell types that can be used in this way are natural killer cells, lymphokine-activated killer cells, cytotoxic T cells and dendritic cells. The only cell-based therapy approved in the US is Dendreon's Provenge, for the treatment of prostate cancer.Interleukin-2 and interferon-α are examples of cytokines, proteins that regulate and coordinate the behaviour of the immune system. They have the ability to enhance anti-tumor activity and thus can be used as cancer treatments. Interferon-α is used in the treatment of hairy-cell leukaemia, AIDS-related Kaposi's sarcoma, follicular lymphoma, chronic myeloid leukaemia and malignant melanoma. Interleukin-2 is used in the treatment of malignant melanoma and renal cell carcinoma.